Nkarta, Inc. Increase (Decrease) in Prepaid Expense and Other Assets
Nkarta, Inc. (NKTX) reported Increase (Decrease) in Prepaid Expense and Other Assets of -$1.17 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-10.
Financial Statements › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets · last filed 2026-08-10
- Nkarta, Inc. increase (decrease) in prepaid expense and other assets for the quarter ending 2026-06-30 was -$275.00K.
- Nkarta, Inc. increase (decrease) in prepaid expense and other assets for the quarter ending 2026-03-31 was -$898.00K, a 276.42% decline year-over-year.
- Nkarta, Inc. increase (decrease) in prepaid expense and other assets for the quarter ending 2025-12-31 was -$835.00K.
- Nkarta, Inc. increase (decrease) in prepaid expense and other assets for the quarter ending 2025-09-30 was -$89.00K, a 107.28% decline year-over-year.
- Nkarta, Inc. increase (decrease) in prepaid expense and other assets for fiscal 2025 was -$2.11M, a 254.80% decline from fiscal 2024.
- Nkarta, Inc. increase (decrease) in prepaid expense and other assets for fiscal 2024 was $1.36M.
- Nkarta, Inc. increase (decrease) in prepaid expense and other assets for fiscal 2023 was -$1.72M, a 215.25% decline from fiscal 2022.
- Nkarta, Inc. increase (decrease) in prepaid expense and other assets for fiscal 2022 was $1.49M, a 66.43% decline from fiscal 2021.
| Period end | Increase (Decrease) in Prepaid Expense and Other Assets 3 month | Increase (Decrease) in Prepaid Expense and Other Assets 6 month | Increase (Decrease) in Prepaid Expense and Other Assets 9 month | Increase (Decrease) in Prepaid Expense and Other Assets 12 month |
|---|---|---|---|---|
| 2026-06-30 | -$275.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-10 | -$1.17M 10-Q · filed 2026-08-10 | -$2.01M derived: sum of 3 quarters · filed 2026-08-10 | -$2.10M derived: sum of 4 quarters · filed 2026-08-10 |
| 2026-03-31 | -$898.00K 10-Q · filed 2026-05-12 | -$1.73M derived: sum of 2 quarters · filed 2026-05-12 | -$1.82M derived: sum of 3 quarters · filed 2026-05-12 | -$3.52M derived: sum of 4 quarters · filed 2026-08-10 |
| 2025-12-31 | -$835.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-25 | -$924.00K derived: sum of 2 quarters · filed 2026-03-25 | -$2.62M derived: sum of 3 quarters · filed 2026-08-10 | -$2.11M 10-K · filed 2026-03-25 |
| 2025-09-30 | -$89.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-10 | -$1.79M derived: sum of 2 quarters · filed 2026-08-10 | -$1.28M 10-Q · filed 2025-11-10 | -$2.97M derived: sum of 4 quarters · filed 2026-08-10 |
| 2025-06-30 | -$1.70M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-10 | -$1.19M 10-Q · filed 2026-08-10 | -$2.88M derived: sum of 3 quarters · filed 2026-08-10 | -$1.66M derived: sum of 4 quarters · filed 2026-08-10 |
| 2025-03-31 | $509.00K 10-Q · filed 2026-05-12 | -$1.18M derived: sum of 2 quarters · filed 2026-05-12 | $41.00K derived: sum of 3 quarters · filed 2026-05-12 | $1.45M derived: sum of 4 quarters · filed 2026-05-12 |
| 2024-12-31 | -$1.69M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-25 | -$468.00K derived: sum of 2 quarters · filed 2026-03-25 | $937.00K derived: sum of 3 quarters · filed 2026-03-25 | $1.36M 10-K · filed 2026-03-25 |
| 2024-09-30 | $1.22M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-10 | $2.63M derived: sum of 2 quarters · filed 2025-11-10 | $3.06M 10-Q · filed 2025-11-10 | $2.43M derived: sum of 4 quarters · filed 2025-11-10 |
| 2024-06-30 | $1.41M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-12 | $1.83M 10-Q · filed 2025-08-12 | $1.21M derived: sum of 3 quarters · filed 2025-08-12 | $780.00K derived: sum of 4 quarters · filed 2025-08-12 |
| 2024-03-31 | $428.00K 10-Q · filed 2025-05-14 | -$195.00K derived: sum of 2 quarters · filed 2025-05-14 | -$625.00K derived: sum of 3 quarters · filed 2025-05-14 | -$1.69M derived: sum of 4 quarters · filed 2025-05-14 |
| 2023-12-31 | -$623.00K derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-26 | -$1.05M derived: sum of 2 quarters · filed 2025-03-26 | -$2.12M derived: sum of 3 quarters · filed 2025-03-26 | -$1.72M 10-K · filed 2025-03-26 |
| 2023-09-30 | -$430.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-07 | -$1.50M derived: sum of 2 quarters · filed 2024-11-07 | -$1.09M 10-Q · filed 2024-11-07 | -$1.18M derived: sum of 4 quarters · filed 2024-11-07 |
| 2023-06-30 | -$1.07M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-13 | -$663.00K 10-Q · filed 2024-08-13 | -$749.00K derived: sum of 3 quarters · filed 2024-08-13 | $4.11M derived: sum of 4 quarters · filed 2024-08-13 |
| 2023-03-31 | $406.00K 10-Q · filed 2024-05-09 | $320.00K derived: sum of 2 quarters · filed 2024-05-09 | $5.18M derived: sum of 3 quarters · filed 2024-05-09 | $3.35M derived: sum of 4 quarters · filed 2024-05-09 |
| 2022-12-31 | -$86.00K derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-21 | $4.77M derived: sum of 2 quarters · filed 2024-03-21 | $2.95M derived: sum of 3 quarters · filed 2024-03-21 | $1.49M 10-K · filed 2024-03-21 |
| 2022-09-30 | $4.86M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-09 | $3.04M derived: sum of 2 quarters · filed 2023-11-09 | $1.57M 10-Q · filed 2023-11-09 | $2.32M derived: sum of 4 quarters · filed 2023-11-09 |
| 2022-06-30 | -$1.82M derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-10 | -$3.28M 10-Q · filed 2023-08-10 | -$2.54M derived: sum of 3 quarters · filed 2023-08-10 | $166.00K derived: sum of 4 quarters · filed 2023-08-10 |
| 2022-03-31 | -$1.46M 10-Q · filed 2023-05-11 | -$713.00K derived: sum of 2 quarters · filed 2023-05-11 | $1.99M derived: sum of 3 quarters · filed 2023-05-11 | $3.80M derived: sum of 4 quarters · filed 2023-05-11 |
| 2021-12-31 | $747.00K derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-16 | $3.45M derived: sum of 2 quarters · filed 2023-03-16 | $5.26M derived: sum of 3 quarters · filed 2023-03-16 | $4.43M 10-K · filed 2023-03-16 |
| 2021-09-30 | $2.70M derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-09 | $4.51M derived: sum of 2 quarters · filed 2022-11-09 | $3.69M 10-Q · filed 2022-11-09 | $3.98M derived: sum of 4 quarters · filed 2022-11-09 |
| 2021-06-30 | $1.81M derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-11 | $987.00K 10-Q · filed 2022-08-11 | $1.28M derived: sum of 3 quarters · filed 2022-08-11 | $4.26M derived: sum of 4 quarters · filed 2022-08-11 |
| 2021-03-31 | -$825.00K 10-Q · filed 2022-05-12 | -$535.00K derived: sum of 2 quarters · filed 2022-05-12 | $2.45M derived: sum of 3 quarters · filed 2022-05-12 | $2.66M derived: sum of 4 quarters · filed 2022-05-12 |
| 2020-12-31 | $290.00K derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-17 | $3.28M derived: sum of 2 quarters · filed 2022-03-17 | $3.48M derived: sum of 3 quarters · filed 2022-03-17 | $3.65M 10-K · filed 2022-03-17 |
| 2020-09-30 | $2.99M derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-10 | $3.19M derived: sum of 2 quarters · filed 2021-11-10 | $3.35M 10-Q · filed 2021-11-10 | $3.85M derived: sum of 4 quarters · filed 2021-11-10 |
| 2020-06-30 | $205.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-12 | $368.00K 10-Q · filed 2021-08-12 | $859.00K derived: sum of 3 quarters · filed 2021-08-12 | |
| 2020-03-31 | $163.00K 10-Q · filed 2021-05-13 | $654.00K derived: sum of 2 quarters · filed 2021-05-13 | ||
| 2019-12-31 | $491.00K derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-25 | $463.00K 10-K · filed 2021-03-25 | ||
| 2019-09-30 | -$28.00K 10-Q · filed 2020-11-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ORAMED PHARMACEUTICALS INC. (ORMP) | $0.199B | 1.13 | |
| Zentalis Pharmaceuticals, Inc. (ZNTL) | United States | $0.196B | -2.48 |
| Foghorn Therapeutics Inc. (FHTX) | United States | $0.213B | -4.43 |
| Eledon Pharmaceuticals, Inc. (ELDN) | United States | $0.219B | -3.23 |
| Whitehawk Therapeutics, Inc. (WHWK) | United States | $0.221B | |
| Fortress Biotech, Inc. (FBIO) | United States | $0.188B | 0.91 |
| ALX ONCOLOGY HOLDINGS INC (ALXO) | United States | $0.187B | -3.52 |
| PepGen Inc. (PEPG) | United States | $0.186B | -1.73 |
| AN2 Therapeutics, Inc. (ANTX) | United States | $0.185B | -4.84 |
| NATURES SUNSHINE PRODUCTS INC (NATR) | United States | $0.228B | 20.51 |